J&J Inks $2.2B Settlement For Off-Label Marketing, Kickbacks

Law360, New York (November 4, 2013, 11:42 AM EST) -- Johnson & Johnson will admit to criminal misconduct and will shell out $2.2 billion to resolve whistleblowers' False Claims Act allegations it showered doctors with kickbacks and illegally promoted off-label uses of three drugs, including the antipsychotic medicine Risperdal, the U.S. Department of Justice said Monday.

The deal, which stems from at least four qui tam complaints, is one of the biggest in U.S. history involving health care fraud and was prompted in large part by marketing of Risperdal for unapproved indications, adding to New Jersey-based J&J's...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.